SURROZEN, INC. Item 8.01 Other Events.
On
We are also continuing our research efforts within our other preclinical programs, including the nomination of SZN-413, a mono Fzd4 bi-specific antibody, as a candidate for the treatment of retinal vascular associated diseases including wet AMD and diabetic retinopathies.
This Current Report contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as "will," "promising," "expect," "continue," "suggest," "target," "potential," "milestone," "opportunities," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding our discovery, research and development activities, in particular its development plans and timeline for our product candidates SZN-1326, SZN-043, SZN-413 and potential future candidates, including anticipated clinical development timelines, and the potential for such product candidates to be used to treat human disease. These statements are based on various assumptions, whether or not identified in this Current Report, and on the current expectations of our management. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability.
Actual events and circumstances are difficult or impossible to predict and will
differ from assumptions. Many actual events and circumstances are beyond our
control. Notwithstanding the developments highlighted above, none of these
product candidates, or potential product candidates, (i) are on the market, (ii)
have gained regulatory approval, (iii) have entered clinical trials or (iv) have
ever been tested in humans. Our ability to achieve any financial benefit from
these product candidates will depend on obtaining regulatory approvals for and
successfully commercializing product candidates. The development of the
Company's product candidates and the realization of any potential benefit from
the items discussed herein are subject to a number of risks and uncertainties,
including the initiation, cost, timing, progress and results of research and
development activities, preclinical or and clinical trials with respect to
SZN-1326, SZN-043, SZN-413, and potential future drug candidates; our ability to
identify, develop and commercialize drug candidates; our ability to advance
SZN-1326, SZN-043, SZN-413, or other future product candidates into, and
successfully complete, preclinical studies and clinical studies; the effects of
the ongoing coronavirus (COVID-19) pandemic or other infectious diseases and
natural disasters on our business; our ability to effectively manage growth and
expand business operations; and those factors discussed in our Quarterly Report
on Form 10-Q under the heading "Risk Factors" and other documents we have filed,
or will file, with the
--------------------------------------------------------------------------------
© Edgar Online, source
